| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Imatinib Mesylate | 4 | 2018 | 327 | 1.45 | Why? |
| Multiple Myeloma | 7 | 2019 | 1064 | 1.42 | Why? |
| Anemia, Aplastic | 3 | 2019 | 167 | 0.99 | Why? |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2018 | 314 | 0.92 | Why? |
| Lymphoma, T-Cell | 2 | 2018 | 70 | 0.90 | Why? |
| Warts | 1 | 2021 | 59 | 0.84 | Why? |
| Bone Marrow | 4 | 2019 | 492 | 0.78 | Why? |
| Neostigmine | 1 | 2018 | 4 | 0.78 | Why? |
| Plasmablastic Lymphoma | 1 | 2019 | 20 | 0.77 | Why? |
| Antilymphocyte Serum | 2 | 2018 | 80 | 0.77 | Why? |
| Cytarabine | 1 | 2019 | 64 | 0.76 | Why? |
| Ear Auricle | 1 | 2019 | 62 | 0.76 | Why? |
| Pyridostigmine Bromide | 1 | 2018 | 29 | 0.76 | Why? |
| Antineoplastic Agents | 9 | 2018 | 3550 | 0.75 | Why? |
| Leukemic Infiltration | 1 | 2018 | 9 | 0.75 | Why? |
| Blepharoptosis | 1 | 2018 | 31 | 0.74 | Why? |
| Prednisolone | 3 | 2018 | 443 | 0.74 | Why? |
| Dermatitis, Exfoliative | 1 | 2019 | 50 | 0.74 | Why? |
| Ichthyosis | 1 | 2018 | 35 | 0.73 | Why? |
| Ear Diseases | 1 | 2019 | 58 | 0.73 | Why? |
| Hypoprothrombinemias | 1 | 2017 | 18 | 0.72 | Why? |
| Leukemia, Plasma Cell | 1 | 2017 | 13 | 0.71 | Why? |
| Neoplasms, Plasma Cell | 1 | 2017 | 83 | 0.71 | Why? |
| Leukemia, Biphenotypic, Acute | 1 | 2017 | 3 | 0.70 | Why? |
| Tuberculosis, Cutaneous | 1 | 2017 | 14 | 0.70 | Why? |
| Hematoma, Subdural | 1 | 2017 | 36 | 0.69 | Why? |
| Leukemia, Promyelocytic, Acute | 1 | 2018 | 60 | 0.69 | Why? |
| Ecthyma | 1 | 2017 | 4 | 0.69 | Why? |
| Prodromal Symptoms | 1 | 2018 | 133 | 0.68 | Why? |
| Nevus, Pigmented | 1 | 2017 | 54 | 0.68 | Why? |
| Cholecalciferol | 1 | 2020 | 246 | 0.67 | Why? |
| Scalp | 1 | 2017 | 82 | 0.65 | Why? |
| Pleural Effusion | 2 | 2018 | 680 | 0.59 | Why? |
| Nail Diseases | 1 | 2017 | 142 | 0.57 | Why? |
| Drug Costs | 1 | 2018 | 313 | 0.56 | Why? |
| Lupus Coagulation Inhibitor | 1 | 2017 | 262 | 0.55 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2018 | 877 | 0.55 | Why? |
| Hodgkin Disease | 1 | 2017 | 204 | 0.55 | Why? |
| Mouth Diseases | 1 | 2017 | 193 | 0.55 | Why? |
| Opportunistic Infections | 2 | 2017 | 602 | 0.52 | Why? |
| Facial Dermatoses | 1 | 2017 | 222 | 0.50 | Why? |
| Drug Eruptions | 1 | 2017 | 319 | 0.50 | Why? |
| Immunophenotyping | 2 | 2018 | 1290 | 0.49 | Why? |
| Myasthenia Gravis | 1 | 2018 | 385 | 0.48 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2019 | 676 | 0.47 | Why? |
| Pseudomonas Infections | 1 | 2017 | 425 | 0.47 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 526 | 0.44 | Why? |
| Immunohistochemistry | 1 | 2019 | 2275 | 0.44 | Why? |
| Antiphospholipid Syndrome | 1 | 2017 | 533 | 0.43 | Why? |
| Mucormycosis | 1 | 2019 | 832 | 0.38 | Why? |
| Skin | 2 | 2018 | 2096 | 0.37 | Why? |
| Antineoplastic Agents, Alkylating | 2 | 2019 | 71 | 0.37 | Why? |
| Skin Neoplasms | 2 | 2018 | 1679 | 0.33 | Why? |
| Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 176 | 0.33 | Why? |
| Vitamin D Deficiency | 1 | 2020 | 1782 | 0.33 | Why? |
| Bortezomib | 2 | 2017 | 125 | 0.32 | Why? |
| Liver Diseases | 2 | 2020 | 2698 | 0.32 | Why? |
| Plasma Cells | 3 | 2019 | 464 | 0.32 | Why? |
| Flow Cytometry | 5 | 2018 | 2393 | 0.32 | Why? |
| Cyclophosphamide | 2 | 2017 | 387 | 0.29 | Why? |
| Vitamin D | 1 | 2020 | 2904 | 0.29 | Why? |
| Health Resources | 1 | 2018 | 2592 | 0.28 | Why? |
| Diagnosis, Differential | 6 | 2019 | 7220 | 0.28 | Why? |
| Neutrophils | 1 | 2021 | 5476 | 0.27 | Why? |
| Edema | 2 | 2017 | 333 | 0.26 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.26 | Why? |
| India | 13 | 2021 | 11875 | 0.26 | Why? |
| Biomarkers | 5 | 2020 | 23361 | 0.26 | Why? |
| Leukemia | 2 | 2018 | 598 | 0.24 | Why? |
| Ferritins | 3 | 2020 | 2055 | 0.24 | Why? |
| Adult | 36 | 2021 | 244371 | 0.22 | Why? |
| Platelet Transfusion | 2 | 2019 | 209 | 0.21 | Why? |
| Biopsy | 3 | 2018 | 2811 | 0.21 | Why? |
| Melphalan | 1 | 2019 | 46 | 0.20 | Why? |
| CD79 Antigens | 1 | 2019 | 5 | 0.20 | Why? |
| Humans | 66 | 2021 | 930598 | 0.20 | Why? |
| Guanylate Cyclase | 1 | 2019 | 10 | 0.20 | Why? |
| Heart Failure | 2 | 2018 | 6638 | 0.20 | Why? |
| Chlorambucil | 1 | 2018 | 3 | 0.20 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.20 | Why? |
| Male | 41 | 2021 | 367725 | 0.20 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1573 | 0.19 | Why? |
| Ki-1 Antigen | 1 | 2019 | 25 | 0.19 | Why? |
| Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2018 | 1 | 0.19 | Why? |
| Core Binding Factor Alpha 2 Subunit | 1 | 2019 | 40 | 0.19 | Why? |
| Bendamustine Hydrochloride | 1 | 2018 | 41 | 0.19 | Why? |
| Hemochromatosis | 1 | 2018 | 20 | 0.19 | Why? |
| Panic Disorder | 1 | 2020 | 84 | 0.19 | Why? |
| Germ-Line Mutation | 1 | 2019 | 86 | 0.19 | Why? |
| CARD Signaling Adaptor Proteins | 1 | 2019 | 70 | 0.19 | Why? |
| Anemia, Hemolytic, Congenital | 1 | 2018 | 4 | 0.19 | Why? |
| Daunorubicin | 1 | 2018 | 33 | 0.19 | Why? |
| Myeloid Differentiation Factor 88 | 1 | 2019 | 109 | 0.19 | Why? |
| Splenic Neoplasms | 1 | 2018 | 20 | 0.19 | Why? |
| Consolidation Chemotherapy | 1 | 2018 | 41 | 0.19 | Why? |
| Lymphoma, Large-Cell, Anaplastic | 1 | 2018 | 24 | 0.19 | Why? |
| Danazol | 1 | 2018 | 12 | 0.19 | Why? |
| Plateletpheresis | 1 | 2017 | 11 | 0.19 | Why? |
| Survivorship | 1 | 2020 | 106 | 0.18 | Why? |
| Arsenicals | 1 | 2018 | 40 | 0.18 | Why? |
| Radiography, Abdominal | 1 | 2019 | 88 | 0.18 | Why? |
| Female | 37 | 2021 | 380317 | 0.18 | Why? |
| Lipid Metabolism, Inborn Errors | 1 | 2017 | 9 | 0.18 | Why? |
| Tobacco Use Disorder | 1 | 2021 | 163 | 0.18 | Why? |
| Antimetabolites, Antineoplastic | 1 | 2019 | 99 | 0.18 | Why? |
| Reticulocytes | 1 | 2018 | 55 | 0.18 | Why? |
| Phytosterols | 1 | 2017 | 22 | 0.18 | Why? |
| Thrombocytosis | 1 | 2017 | 21 | 0.18 | Why? |
| Procarbazine | 1 | 2017 | 14 | 0.18 | Why? |
| Purpura, Thrombocytopenic | 1 | 2017 | 12 | 0.18 | Why? |
| Lichenoid Eruptions | 1 | 2017 | 22 | 0.18 | Why? |
| Transplantation, Autologous | 1 | 2019 | 364 | 0.18 | Why? |
| Metabolism, Inborn Errors | 1 | 2018 | 51 | 0.18 | Why? |
| Acid-Base Imbalance | 1 | 2018 | 46 | 0.18 | Why? |
| Histiocytosis, Non-Langerhans-Cell | 1 | 2017 | 6 | 0.18 | Why? |
| Mucorales | 1 | 2019 | 92 | 0.18 | Why? |
| Hypopigmentation | 1 | 2017 | 28 | 0.17 | Why? |
| Bacterial Outer Membrane Proteins | 1 | 2017 | 60 | 0.17 | Why? |
| Bone Marrow Diseases | 1 | 2017 | 27 | 0.17 | Why? |
| Pharmacogenetics | 1 | 2019 | 222 | 0.17 | Why? |
| Biopsy, Fine-Needle | 1 | 2019 | 274 | 0.17 | Why? |
| Oxides | 1 | 2018 | 77 | 0.17 | Why? |
| Kruppel-Like Transcription Factors | 1 | 2018 | 91 | 0.17 | Why? |
| Erythema Nodosum | 1 | 2018 | 38 | 0.17 | Why? |
| Immunoglobulin Light Chains | 1 | 2018 | 62 | 0.17 | Why? |
| Secretory Vesicles | 1 | 2017 | 38 | 0.17 | Why? |
| Bone Marrow Cells | 1 | 2019 | 186 | 0.17 | Why? |
| Tretinoin | 1 | 2018 | 99 | 0.17 | Why? |
| Hyperpigmentation | 1 | 2017 | 42 | 0.17 | Why? |
| Sickle Cell Trait | 1 | 2018 | 59 | 0.17 | Why? |
| Antibiotics, Antineoplastic | 1 | 2018 | 128 | 0.17 | Why? |
| Splenic Infarction | 1 | 2018 | 67 | 0.17 | Why? |
| Endocrine System Diseases | 1 | 2021 | 282 | 0.17 | Why? |
| Leukemia, Myeloid | 1 | 2018 | 76 | 0.17 | Why? |
| Mannans | 1 | 2018 | 218 | 0.17 | Why? |
| Transplantation Conditioning | 1 | 2019 | 323 | 0.17 | Why? |
| Immunocompetence | 1 | 2019 | 280 | 0.17 | Why? |
| Propanolamines | 1 | 2016 | 47 | 0.17 | Why? |
| GPI-Linked Proteins | 1 | 2018 | 317 | 0.17 | Why? |
| Protein Kinase Inhibitors | 2 | 2017 | 1585 | 0.16 | Why? |
| Erythropoietin | 1 | 2018 | 167 | 0.16 | Why? |
| Tertiary Care Centers | 6 | 2021 | 8248 | 0.16 | Why? |
| Etoposide | 1 | 2017 | 115 | 0.16 | Why? |
| Natriuretic Peptides | 1 | 2017 | 66 | 0.16 | Why? |
| Altitude Sickness | 1 | 2018 | 95 | 0.16 | Why? |
| Histoplasmosis | 1 | 2017 | 83 | 0.16 | Why? |
| beta-Glucans | 1 | 2018 | 176 | 0.16 | Why? |
| Skin Diseases, Vesiculobullous | 1 | 2017 | 112 | 0.16 | Why? |
| Image-Guided Biopsy | 1 | 2018 | 185 | 0.16 | Why? |
| Genetic Diseases, Inborn | 1 | 2017 | 190 | 0.15 | Why? |
| Hemoglobinuria, Paroxysmal | 1 | 2017 | 116 | 0.15 | Why? |
| Carbazoles | 1 | 2016 | 120 | 0.15 | Why? |
| Thalidomide | 1 | 2018 | 247 | 0.15 | Why? |
| Hypercholesterolemia | 1 | 2017 | 175 | 0.15 | Why? |
| Mutation, Missense | 2 | 2018 | 863 | 0.15 | Why? |
| Myeloid Cells | 1 | 2021 | 808 | 0.15 | Why? |
| Thrombocytopenia | 2 | 2019 | 2093 | 0.15 | Why? |
| Adaptation, Physiological | 1 | 2018 | 359 | 0.15 | Why? |
| Respiratory Insufficiency | 1 | 2017 | 7301 | 0.15 | Why? |
| Antineoplastic Agents, Hormonal | 1 | 2017 | 203 | 0.15 | Why? |
| Hematology | 2 | 2019 | 649 | 0.15 | Why? |
| Mutation | 4 | 2019 | 12376 | 0.14 | Why? |
| beta-Thalassemia | 1 | 2018 | 200 | 0.14 | Why? |
| Peripheral Nervous System Diseases | 1 | 2017 | 193 | 0.14 | Why? |
| Hospitals, General | 1 | 2020 | 711 | 0.14 | Why? |
| Immunologic Tests | 1 | 2018 | 445 | 0.14 | Why? |
| Altitude | 1 | 2018 | 311 | 0.14 | Why? |
| Fibrinogen | 1 | 2020 | 1048 | 0.14 | Why? |
| Mouth Mucosa | 1 | 2017 | 323 | 0.14 | Why? |
| Intestinal Diseases | 1 | 2017 | 231 | 0.14 | Why? |
| Invasive Fungal Infections | 1 | 2018 | 274 | 0.14 | Why? |
| Doxorubicin | 1 | 2016 | 313 | 0.14 | Why? |
| Conservative Treatment | 1 | 2017 | 349 | 0.14 | Why? |
| Myeloproliferative Disorders | 1 | 2019 | 507 | 0.14 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2018 | 403 | 0.14 | Why? |
| Blood Proteins | 1 | 2018 | 551 | 0.13 | Why? |
| Psychosocial Support Systems | 1 | 2020 | 710 | 0.13 | Why? |
| Coronary Stenosis | 1 | 2017 | 273 | 0.13 | Why? |
| Acinetobacter baumannii | 1 | 2017 | 378 | 0.13 | Why? |
| Adolescent | 11 | 2021 | 86841 | 0.13 | Why? |
| Neoplasm Proteins | 1 | 2019 | 501 | 0.13 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.13 | Why? |
| Alcoholism | 1 | 2021 | 691 | 0.12 | Why? |
| Mitral Valve Insufficiency | 1 | 2017 | 302 | 0.12 | Why? |
| Hemoglobins | 1 | 2018 | 958 | 0.12 | Why? |
| Middle Aged | 25 | 2021 | 270681 | 0.12 | Why? |
| Lymphoma | 1 | 2018 | 522 | 0.12 | Why? |
| Women's Health | 1 | 2017 | 444 | 0.12 | Why? |
| Hematologic Tests | 1 | 2017 | 521 | 0.12 | Why? |
| Young Adult | 13 | 2021 | 93724 | 0.11 | Why? |
| Pseudomonas aeruginosa | 1 | 2017 | 652 | 0.11 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2018 | 698 | 0.11 | Why? |
| Steroids | 1 | 2017 | 904 | 0.11 | Why? |
| Medical Staff, Hospital | 1 | 2021 | 1258 | 0.10 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2017 | 552 | 0.10 | Why? |
| Rituximab | 1 | 2018 | 1096 | 0.10 | Why? |
| Neoplasm Recurrence, Local | 1 | 2018 | 1063 | 0.10 | Why? |
| Virulence | 1 | 2017 | 2172 | 0.10 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2018 | 1153 | 0.10 | Why? |
| Anger | 2 | 2020 | 123 | 0.10 | Why? |
| Robotic Surgical Procedures | 1 | 2018 | 787 | 0.10 | Why? |
| Depressive Disorder | 1 | 2020 | 1236 | 0.10 | Why? |
| Phenotype | 2 | 2018 | 4037 | 0.09 | Why? |
| Fatal Outcome | 1 | 2019 | 3438 | 0.09 | Why? |
| Membrane Glycoproteins | 1 | 2018 | 2273 | 0.09 | Why? |
| Dietary Supplements | 1 | 2020 | 2251 | 0.09 | Why? |
| Ventricular Dysfunction, Left | 1 | 2016 | 993 | 0.09 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 1458 | 0.09 | Why? |
| Survivors | 1 | 2020 | 2619 | 0.09 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.09 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.09 | Why? |
| Treatment Outcome | 6 | 2019 | 51732 | 0.09 | Why? |
| Immunization, Passive | 2 | 2021 | 10067 | 0.09 | Why? |
| Homozygote | 2 | 2018 | 230 | 0.09 | Why? |
| Patient Care Management | 1 | 2019 | 1514 | 0.08 | Why? |
| Heterozygote | 2 | 2018 | 249 | 0.08 | Why? |
| Pedigree | 2 | 2019 | 502 | 0.08 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.08 | Why? |
| C-Reactive Protein | 2 | 2020 | 7972 | 0.08 | Why? |
| Cardiomyopathies | 1 | 2016 | 997 | 0.08 | Why? |
| Aged | 12 | 2021 | 215776 | 0.08 | Why? |
| Hematologic Neoplasms | 2 | 2017 | 2105 | 0.08 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.08 | Why? |
| Eye Diseases | 1 | 2017 | 1150 | 0.08 | Why? |
| Antifungal Agents | 1 | 2017 | 1828 | 0.08 | Why? |
| Dexamethasone | 1 | 2017 | 2055 | 0.08 | Why? |
| Liver Neoplasms | 1 | 2018 | 1666 | 0.08 | Why? |
| Occupational Diseases | 1 | 2021 | 2787 | 0.07 | Why? |
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 2426 | 0.07 | Why? |
| Blood Cells | 2 | 2018 | 104 | 0.07 | Why? |
| Australia | 1 | 2018 | 6306 | 0.07 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.07 | Why? |
| Glucocorticoids | 2 | 2017 | 4431 | 0.07 | Why? |
| Medical Oncology | 2 | 2018 | 3826 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.07 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.07 | Why? |
| Skin Diseases | 1 | 2020 | 2509 | 0.06 | Why? |
| Sex Factors | 2 | 2017 | 11014 | 0.06 | Why? |
| Health Care Rationing | 1 | 2018 | 2558 | 0.06 | Why? |
| Cough | 1 | 2017 | 4891 | 0.06 | Why? |
| Immunosuppressive Agents | 2 | 2018 | 6331 | 0.06 | Why? |
| Coronary Artery Disease | 1 | 2017 | 2570 | 0.06 | Why? |
| Microscopy | 2 | 2018 | 414 | 0.06 | Why? |
| Disease Management | 2 | 2018 | 6841 | 0.06 | Why? |
| Radiography, Thoracic | 1 | 2019 | 5486 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2018 | 5150 | 0.06 | Why? |
| Irritable Mood | 1 | 2020 | 93 | 0.05 | Why? |
| Child | 6 | 2021 | 70012 | 0.05 | Why? |
| Asia | 2 | 2018 | 2399 | 0.05 | Why? |
| Guilt | 1 | 2020 | 74 | 0.05 | Why? |
| Shame | 1 | 2020 | 53 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2019 | 8041 | 0.05 | Why? |
| Hemochromatosis Protein | 1 | 2018 | 21 | 0.05 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.05 | Why? |
| Child, Preschool | 3 | 2018 | 36283 | 0.05 | Why? |
| Emotional Adjustment | 1 | 2020 | 127 | 0.05 | Why? |
| Erythrocytes, Abnormal | 1 | 2018 | 6 | 0.05 | Why? |
| Mentally Ill Persons | 1 | 2020 | 103 | 0.05 | Why? |
| Heredity | 1 | 2018 | 37 | 0.05 | Why? |
| Type C Phospholipases | 1 | 2017 | 6 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.05 | Why? |
| Albumins | 1 | 2020 | 324 | 0.05 | Why? |
| Galactose | 1 | 2018 | 201 | 0.04 | Why? |
| Life Change Events | 1 | 2020 | 208 | 0.04 | Why? |
| Consensus Development Conferences as Topic | 1 | 2018 | 93 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.04 | Why? |
| Hope | 1 | 2020 | 210 | 0.04 | Why? |
| Erythrocyte Count | 1 | 2018 | 137 | 0.04 | Why? |
| Bilirubin | 1 | 2020 | 503 | 0.04 | Why? |
| Clinical Chemistry Tests | 1 | 2018 | 82 | 0.04 | Why? |
| Infant | 2 | 2018 | 30274 | 0.04 | Why? |
| Waldenstrom Macroglobulinemia | 1 | 2018 | 85 | 0.04 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.04 | Why? |
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 243 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.04 | Why? |
| Stress, Psychological | 1 | 2020 | 10231 | 0.04 | Why? |
| Induction Chemotherapy | 1 | 2017 | 149 | 0.04 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.04 | Why? |
| Death Certificates | 1 | 2017 | 130 | 0.04 | Why? |
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 3633 | 0.04 | Why? |
| Organizational Policy | 1 | 2021 | 694 | 0.04 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.04 | Why? |
| Professional-Patient Relations | 1 | 2020 | 426 | 0.04 | Why? |
| Automation | 1 | 2018 | 429 | 0.04 | Why? |
| Fear | 2 | 2020 | 3607 | 0.04 | Why? |
| Models, Organizational | 1 | 2021 | 908 | 0.04 | Why? |
| Virulence Factors | 1 | 2017 | 338 | 0.03 | Why? |
| Family Health | 1 | 2020 | 731 | 0.03 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Anxiety | 1 | 2020 | 17311 | 0.03 | Why? |
| Cytogenetics | 1 | 2013 | 4 | 0.03 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.03 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.03 | Why? |
| Acinetobacter Infections | 1 | 2017 | 273 | 0.03 | Why? |
| Plasmapheresis | 1 | 2018 | 437 | 0.03 | Why? |
| Drug Resistance, Neoplasm | 1 | 2018 | 447 | 0.03 | Why? |
| Counseling | 1 | 2020 | 747 | 0.03 | Why? |
| Cyclosporine | 1 | 2018 | 449 | 0.03 | Why? |
| Liver Function Tests | 1 | 2020 | 1325 | 0.03 | Why? |
| Histocytochemistry | 1 | 2013 | 88 | 0.03 | Why? |
| Beijing | 1 | 2017 | 912 | 0.03 | Why? |
| Reference Standards | 1 | 2018 | 1163 | 0.03 | Why? |
| Demography | 1 | 2021 | 1660 | 0.03 | Why? |
| Hospital Administration | 1 | 2020 | 650 | 0.03 | Why? |
| DNA Primers | 1 | 2018 | 1170 | 0.03 | Why? |
| Cytological Techniques | 1 | 2013 | 79 | 0.03 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.03 | Why? |
| Echocardiography | 2 | 2017 | 3661 | 0.03 | Why? |
| Stem Cell Transplantation | 1 | 2018 | 531 | 0.03 | Why? |
| Antigens, CD | 1 | 2018 | 984 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2019 | 25144 | 0.03 | Why? |
| Antibodies, Viral | 2 | 2021 | 51949 | 0.03 | Why? |
| Social Isolation | 2 | 2020 | 5932 | 0.03 | Why? |
| Disease Progression | 2 | 2020 | 13580 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.02 | Why? |
| Animals | 1 | 2018 | 78931 | 0.02 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.02 | Why? |
| Hospitals, University | 1 | 2021 | 4173 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Coronary Angiography | 1 | 2017 | 2275 | 0.02 | Why? |
| Videoconferencing | 1 | 2020 | 2081 | 0.02 | Why? |
| Ventricular Function, Left | 1 | 2016 | 1555 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2017 | 1476 | 0.02 | Why? |
| Personnel, Hospital | 1 | 2020 | 2273 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Methylprednisolone | 1 | 2017 | 2107 | 0.02 | Why? |
| Stroke Volume | 1 | 2016 | 2153 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2018 | 3788 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Software | 1 | 2018 | 2501 | 0.02 | Why? |
| Personal Protective Equipment | 2 | 2021 | 15978 | 0.02 | Why? |
| Thrombophilia | 1 | 2018 | 1935 | 0.02 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Developing Countries | 1 | 2021 | 4283 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.02 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.01 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Adaptation, Psychological | 1 | 2020 | 4996 | 0.01 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.01 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.01 | Why? |
| Healthcare Disparities | 1 | 2018 | 3893 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2017 | 43792 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.01 | Why? |
| Cohort Studies | 1 | 2019 | 36005 | 0.01 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2018 | 10697 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
| China | 1 | 2017 | 50654 | 0.01 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.00 | Why? |